TriangleHEALTH PROFESSIONAL · SOURCE READING
BR versus FCR
Source: Chronic Lymphocytic Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 25, 2025 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.
Evidence (BR vs. FCR):
The German CLL Study Group compared BR versus FCR as first-line therapy in patients with CLL who required therapy.[23]
Source links and citations
The German CLL Study Group compared BR versus FCR as first-line therapy in patients with CLL who required therapy.[23]
With a median follow-up of 37.1 months, the median PFS was better for patients who received FCR (55.2 months vs. 41.7 months) (HR, 1.64; 90% CI, 1.31–2.06; P = .001), but there was no difference in the OS rate at 3 years (91% vs. 92%, not significant).[23][Level of evidence B1]
Source links and citations
The German CLL Study Group compared BR versus FCR as first-line therapy in patients with CLL who required therapy.[23]
In patients older than 65 years, there was no difference in PFS between the two arms, but more infections occurred with FCR than with BR (grade 3 to 5 infection, 47% vs. 27%).
Publication references
Read the original reference and check its publication notices.
Preserved source evidence · Not medical advice